

2023

Steinebach C, Bricelj A, Murgai A, Sosič I, Bischof L, Ng YLD, Heim C, Maiwald S, Proj M, Voget R, Feller F, Košmrlj J, Sapozhnikova V, Schmidt A, Zuleeg MR, Lemnitzer P, Mertins P, Hansen FK, Gütschow M, Krönke J, Hartmann MD; Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs; *J. Med. Chem.* 2023, 66, 14513-14543.

Günther M, Hentschel L, Schuler M, Müller T, Ko YD, Schmidet-Wolf I, Jaehde U; Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers, *BMC Cancer* 2023; 23:629, <https://doi.org/10.1186/s12885-023-11115-7>

Schmulenson E, Zimmermann N, Müller L, Kapsa S, Sihinevich I, Jaehde U; Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil, *Cancer Medicine* 2023;12:2580-2589 DOI: 10.1002/cam4.5118

Pfeifer V, Weber H, Wang Y, Schlesinger M, Gorzelanny C, Bendas G; Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling. *Int J Mol Sci* 2023; 24(6). doi: 10.3390/ijms24065452.

König P, Zhulenko R, Suparman E, Hoffmeister H, Bückreiß N, Ott I, Bendas G; A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis. *Cancer Chemother Pharmacol* 2023. doi: 10.1007/s00280-023-04548-1

Hassan N, Bückreiß N, Efinger J, Schulz-Fincke M, König P, Greve B, Bendas G, Götte M; The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor. *Cells* 2023; 12(6). doi: 10.3390/cells12060910.

Feller F, Hansen FK; Targeted Protein Degradation of Histone Deacetylases by Hydrophobically Tagged Inhibitors. *ACS Med. Chem. Lett.* 2023. doi: 10.1021/acsmchemlett.3c00468

Huber ME, Wurnig S, Toy L, Weiler C, Merten N, Kostenis E, Hansen FK, Schiedel M;

Fluorescent Ligands Enable Target Engagement Studies for the Intracellular Allosteric Binding Site of the Chemokine Receptor CXCR2. *Journal of Medicinal Chemistry* 2023. doi: 10.1021/acs.jmedchem.3c00769.

Kraft FB, Hanl M, Feller F, Schäker-Hübner L, Hansen FK; Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy. *Pharmaceuticals* 2023; 16(3):356. Verfügbar unter: <https://www.mdpi.com/1424-8247/16/3/356>.

Bachmann LM, Hanl M, Feller F, Sinatra L, Schöler A, Pietzsch J, Laube M, Hansen FK; Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors.

Molecules 2023; 28(3):1061. Verfügbar unter: <https://www.mdpi.com/1420-3049/28/3/1061>

Wurnig S, Vogt M, Hogenkamp J, Dienstbier N, Borkhardt A, Bhatia S, Hansen FK
Development of the first geldanamycin-based HSP90 degraders.
Frontiers in Chemistry 2023; 11:1219883. doi: 10.3389/fchem.2023.1219883

Sinatra L, Vogelmann A, Friedrich F, Tararina MA, Neuwirt E, Colcerasa A, König P, Toy L, Yesiloglu TZ, Hilscher S, Gaitzsch L, Papenkordt N, Zhai S, Zhang L, Romier C, Einsle O, Sippl W, Schutkowski M, Gross O, Bendas G, Christianson DW, Hansen FK, Jung M, Schiedel M; Development of First-in-Class

Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. *Journal of Medicinal Chemistry* 2023; 66(21):14787–814. doi: 10.1021/acs.jmedchem.3c01385.

Dauer K, Kayser K, Ellwanger F, Overbeck A, Kwade A, Karbstein HP, Wagner KG; Highly protein-loaded melt extrudates produced by small-scale ram and twin-screw extrusion – evaluation of extrusion process design on protein stability by experimental and numerical approaches, *International Journal of Pharmaceutics*: X, July 2023. DOI: 10.1016/j.ijpx.2023.100196

Hopp MT, Holze J, Lauber F, Holtkamp L, Rathod DC, Miteva MA, Prestes EB, Geyer M, Manoury B, Merle NS, Roumenina LT, Bozza MT, Weindl G, Imhof D; Insights into the molecular basis and mechanism of heme-triggered TLR4 signalling: The role of heme-binding motifs in TLR4 and MD2. *Immunology*. 2023. doi: 10.1111/imm.13708

Bockstiegel J, Engelhardt J, Weindl G; P2X7 receptor activation leads to NLRP3-independent IL-1 β release by human macrophages. *Cell Commun. Signal.* 2023, 21, 335. doi: 10.1186/s12964-023-01356-1

Lopez V, Schuh HJM, Mirza S, Vaassen VJ, Schmidt MS, Sylvester K, Idris RM, Renn C, Schäkel L, Pelletier J, Sévigny J, Naggi A, Scheffler B, Lee SY, Bendas G, Müller CE; Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) – a promising target for the immunotherapy of cancer.

Front. Immunol. 2023, 14, 1173634; doi: 10.3389/fimmu.2023.1173634.

Voss JH, Al-Hroub H, Gedschold R, Dietrich JM, Gaffal E, Toma M, Kehraus S, König G M, Brust P, Fleischmann BK, Wenzel D, Deuther-Conrad W, Müller CE; Imaging of G α q proteins in mouse and human organs and tissues. *Pharmaceutics* 2023, 15, 57; <https://doi.org/10.3390/pharmaceutics15010057>.

Geiger N, Diesendorf V, Roll V, Eva-Maria König, Obernolte H, Sewald K, Breidenbach J, Pillaiyar T, Gütschow M, Müller CE, Jochen Bodem; Cell type-specific anti-viral effects of novel SARS-CoV-2 main protease inhibitors. *Int. J. Mol. Sci.* 2023, 24, 3972; <https://doi.org/10.3390/ijms24043972>.

Tsukamoto Y, Hiono T, Yamada S, Matsuno K, Faist A, Claff T, Hou J, Namasivayam V, vom Hemdt A, Sugimoto S, Ng JY, Christensen MH, Tesfamariam YM, Wolter S, Juranek, Zillinger T, Bauer S, Hirokawa T, Schmidt FI, Kochs G, Shimojima M, Huang YS, Pichlmair A, Kümmerer BM, Sakoda Y, Schlee M, Brunotte L, Müller CE, Igarashi M, Kato H; Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication. *Science* 2023, 379, 586-591; <https://doi.org/10.3390/ijms24043972>

Claff T, Schlegel JG, Voss JH, Vaaßen VJ, Weiße RH, Cheng RKY, Markovic-Mueller S, Bucher D, Sträter N, Müller CE; Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction. *Commun. Chem.* 2023, 6, 106; <https://doi.org/10.1038/s42004-023-00894-6>

Voss JH, Crüsemann M, Bartling CRO, König GM, Strømgaard K, Müller, CE; Structure-affinity and structure-residence time relationships of macrocyclic G α q protein inhibitors. *iScience* 2023, 26, 106492; <https://doi.org/10.1016/j.isci.2023.106492>

Bi C, Schäkel L, Mirza S, Sylvester K, Pelletier J, Lee SY, Pillaiyar, Sévigny J, Müller CE; Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39. *Bioorg. Chem.* 2023, 135, 106360; <https://doi.org/10.1016/j.bioorg.2023.106460>.

Giraulo C, Turiello R, Orlando L, Leonardelli S, Landsberg J, Belvedere R, Rolshoven G, Müller CE, Hölzel M, Morello S; The CD73 is induced by TGF- β 1 triggered by nutrient deprivation and highly expressed in dedifferentiated human melanoma. *Biomed. Pharmacother.* 2023, 165, 115225; <https://doi.org/j.biophar.2023.115225>.

Wollnitzke P, Wagner R, Afsar SY, Werner M, Gedschold R, Müller CE, Werz O, van Echten-Deckert G, Menche D; Synthesis and biological evaluation of simplified ajudazol derivatives reveal potent 5-lipoxygenase inhibition and considerable apoptotic activity in neuroblastoma cells. *Bioorg. Med. Chem. Lett.* 2023, 94, 129464; <https://doi.org/10.1016/j.bmcl.2023.129464>.

Marx D, Mohamed Wessam Alnouri, Clemens S, Gedschold R, Riedel Y, Al Hamwi G, Pillaiyar T, Hockemeyer J, Namasivayam V, Müller CE; Discovery of potent agonists for the predominant variant of the orphan MAS-related G protein-coupled receptor X4 (MRGPRX4). *J. Med. Chem.* 2023, 66, 15674-15698; <https://doi.org/10.3390/biom13071079>.

Zhang HJ, Ociepa M, Nassir M, Zheng B, Lewicki S, Salmaso V, Baburi H, Nagel J, Mirza S, Büschbell B, Al-Hroub H, Perzanowska O, Lin Z, Schmidt MA, Eastgate MD, Jacobson KA, Müller CE, Kowalska J, Jemielity J, Baran PS; Stereocontrolled access to thioisosteres of nucleoside di- and triphosphates. *Nature Chemistry* 2023, <https://doi.org/10.1038/s41557-023-01347-2>.

König B, Watson PR, Reßling N, Cragin AD, Schäker-Hübner L, Christianson DW, Hansen FK: Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6. *J. med. Chem.*

Vu LP, Diehl CJ, Casement R, Bond AG, Steinebach C, Strašek N, Bricelj A, Perdih A, Schnakenburg G, Sosič I, Ciulli A, Gütschow M: Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1 α (HIF-1 α) Stabilizers. *J. Med. Chem.* 2023, 66, 12776-12811.

Keuler T, Wolf V, Lemke C, Voget R, Braune A, Gütschow M: Fluorogenic Substrates and Pre-column Derivatization for Monitoring the Activity of Bile Salt Hydrolase from *Clostridium perfringens*. *Bioorg. Chem.* 2023, 138, 106574

Pepanian A, Binby FA, Roy S, Nubbemeyer B, Koley A, Rhodes CA; Ammer H, Pei D, Ghosh P, Imhof D. Bicyclic peptide library screening for the identification of G α i protein modulators. *J. Med. Chem.*

Judith Bockstiegel, Silas L Wurnig, Jonas Engelhardt, Jana Enns, Finn K Hansen, Günther Weindl (2023) Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1 β release. *Biochem Pharmacol* 215: 115693. doi: 10.1016/j.bcp.2023.115693

Tahoun M, Engener M, Svolacchis L, Sander M, Müller CE: *Molecular Taphonomy of Heme: Chemical Degradation of Hemin under Presumed Fossilization Conditions*. *Molecules* 2023

Javed H, Singh S, Urs Ramarajje S, Oldenburg J, Biswas A. *Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beypong*. *Blood Reviews*

Dauer K, Wagner KG. *Micro-Scale Vacuum Compression Molding as a Predictive Screening Tool of Protein Integrity for Potential Hot-Melt extrusion Processes*. *Pharmaceutics*

Ng YLD, Bricelj A, Jansen JA, Murgai A, Peter K, Donovan KA, Gütschow M, Krönke J, Steinebach C, Sosič I: Heterobifunctional Ligase Recruiters Enable Pan-Degradation of Inhibitor of Apoptosis Proteins. *J. Med. Chem.* 2023, 66, 4703-4733

Kuchta R, Heim C, Herrmann A, Maiwald S, Ng YLD, Sosič I, Keuler T, Krönke J, Gütschow M, Hartmann MD, Steinebach C: Accessing Three-Branched High-Affinity Cereblon Ligands for Molecular Glue and Protein Degradation Design. *RSC Chem. Biol.* 2023, 4, 229-234.

Pöstges F, Kayser K, Appelhaus J, Monschke M, Gütschow M, Steinebach C, Wagner KG: Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs. *Pharmaceutics* 2023, 15, 156.